Abbou C C, Beaumont V, Chopin D, Deburge J P, Beaumont J L, Auvert J
Nouv Presse Med. 1980 Mar 29;9(15):1067-71.
A retrospective study of immunologic behavior of patients suffering from cancer of the prostate and treated with oestrogens permits the proposal of the utilisation of a test that separates a high thromboembolic risk population due to oestrogens from a population that can benefit from this hormonotherapy. The so-called "oestrogen tolerance test" consists of seeking the presence of immune complexes by the method of precipitation of serum by 25% saturated ammonium sulphate. The group of patients where precipitates exceeds 700 micrograms/ml has a thrombo-embolic risk above 30% (41% in our series with serious complications such as pulmonary embolus and arterial thrombosis. The group of patients where precipitates are less than 300 micrograms/ml has a lower risk of arterial thrombosis (2,5%) and the observed accidents are benign. Finally, a test test when precipitate exceed 700 micrograms/ml should exclude diethylstilboestrol treatment.
一项对前列腺癌患者接受雌激素治疗后的免疫行为的回顾性研究，使得一种检测方法的应用建议得以提出，该检测可将因雌激素导致高血栓栓塞风险的人群与可从这种激素治疗中获益的人群区分开来。所谓的“雌激素耐受性检测”，是通过用25%饱和硫酸铵沉淀血清的方法来寻找免疫复合物的存在。沉淀物超过700微克/毫升的患者组，其血栓栓塞风险高于30%（在我们的系列研究中为41%，伴有肺栓塞和动脉血栓形成等严重并发症）。沉淀物低于300微克/毫升的患者组，其动脉血栓形成风险较低（2.5%），且观察到的不良事件较为轻微。最后，当沉淀物超过700微克/毫升时进行的一项检测应排除己烯雌酚治疗。
